论文部分内容阅读
目的观察恩替卡韦(ETV)对慢性重症肝炎的疗效和安全性。方法对60例早中期慢性乙型重型肝炎患者分为对照组(30例)和治疗组(30例),分别采用综合治疗和加用恩替卡韦的治疗,定期观察肝功能主要指标、患者的治愈率、好转率。结果恩替卡韦治疗的疗效较明显,治疗组与对照组在改善肝功能方面有显著性差异。结论恩替卡韦治疗慢性乙型肝炎取得了较好的疗效,值得临床进一步应用。
Objective To observe the efficacy and safety of entecavir in chronic severe hepatitis. Methods Sixty patients with chronic hepatitis B in early and middle stage were divided into control group (30 cases) and treatment group (30 cases). The patients were treated with combined therapy and entecavir, and the main indexes of liver function were observed regularly. The cure rate Improvement rate. Results Efficacy of entecavir treatment was more obvious, the treatment group and the control group in the improvement of liver function were significantly different. Conclusion Entecavir treatment of chronic hepatitis B has achieved good results, it is worth further clinical application.